Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GFS101A
- Development stage
- Discontinued
- Lead developer
- GenFleet Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GFS101A is a monoclonal antibody therapeutic developed by Genfleet Therapeutics (Shanghai) for the treatment of solid tumors. It is a biological product intended for oncology indications, specifically advanced or metastatic solid tumors. The drug was studied in combination with toripalimab, an anti-PD-1 monoclonal antibody, to evaluate its safety, tolerability, pharmacokinetics, and efficacy in patients with advanced solid tumors. The clinical trial (NCT05165849) was withdrawn before enrollment began[1][3][5]. Detailed mechanism of action and specific molecular targets for GFS101A have not been disclosed in public sources as of June 2025[2][4][5].
Beyond the preview
Go deeper on GFS101A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GFS101A.